PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 76220

Title: Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03674017

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor

Reviewer’s Country/Territory: China

Author’s Country/Territory: India

Manuscript submission date: 2022-03-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-08 09:59

Reviewer performed review: 2022-03-09 08:13

Review time: 22 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[Y] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[Y] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

I generally agree with the statement in the letter rather than the original review. Although I may be biased, the drug selection between DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists should be mainly based on the baseline risk of cardiovascular diseases and potential contradiction but rather than age per se.
Name of journal: *World Journal of Diabetes*

Manuscript NO: 76220

Title: Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03834515

Position: Peer Reviewer

Academic degree: BMed, MD, MSc

Professional title: Chief Physician, Director, Professor

Reviewer’s Country/Territory: China

Author’s Country/Territory: India

Manuscript submission date: 2022-03-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-24 01:23

Reviewer performed review: 2022-03-25 03:04

Review time: 1 Day and 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review:</td>
<td>Anonymous</td>
<td>Onymous</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

1. The authors made a successful replenish to the minireview recently published in the journal, attaching importance to the comparison between SGLT-2Is and DPP-4Is. While agreeing with the inferiority of DPP-4Is compared the GLP-1RAs, they presented their hesitation about whether DPP-4Is have superiority over SGLT-2Is in elderly patients, and listed their reasons based on several clinical trials, meta-analysis and guidelines. 

2. The title and key words are compatible with the focus of the manuscript. However, the abstract seems to fail to summarize the core tips and the well contribution of the manuscript, lacking the description about the main points and the final conclusion. 

3. The relationship between DPP-4Is and heart failure remains controversial in recent years, while there have been several meta-analyses studied the extent to which DPP-4Is affect the risk of heart failure in patients with type 2 diabetes, which seems to be overlooked in the part of cardiovascular effect in this manuscript. 

4. The authors find an interesting phenomenon about the baseline HbA1c value and the lowering effect of SGLT-2Is vs. DPP-4Is. It would be better if they can propose some potential mechanism about the truth.